Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
7.09
-0.24 (-3.27%)
At close: Dec 5, 2025, 4:00 PM EST
7.15
+0.06 (0.85%)
After-hours: Dec 5, 2025, 7:58 PM EST
Myriad Genetics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Myriad Genetics stock ranges from a low of $6.00 to a high of $29. The average analyst price target of $12.58 forecasts a 77.43% increase in the stock price over the next year.
Price Target: $12.58 (+77.43%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Myriad Genetics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 9 | 9 | 9 | 9 | 9 | 8 |
| Sell | 3 | 3 | 3 | 3 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $8.5 | Buy | Maintains | $9 → $8.5 | +19.89% | Nov 11, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $6 → $6.5 | Hold | Maintains | $6 → $6.5 | -8.32% | Nov 5, 2025 |
| TD Cowen | TD Cowen | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +26.94% | Nov 4, 2025 |
| UBS | UBS | Hold Maintains $6 → $8 | Hold | Maintains | $6 → $8 | +12.83% | Nov 4, 2025 |
| Scotiabank | Scotiabank | Buy → Hold Downgrades $20 → $6 | Buy → Hold | Downgrades | $20 → $6 | -15.37% | May 21, 2025 |
Financial Forecast
Revenue This Year
838.40M
from 837.60M
Increased by 0.10%
Revenue Next Year
882.64M
from 838.40M
Increased by 5.28%
EPS This Year
0.01
from -1.41
EPS Next Year
0.07
from 0.01
Increased by 669.21%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 867.8M | 941.1M | |||
| Avg | 838.4M | 882.6M | |||
| Low | 801.8M | 818.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.6% | 12.3% | |||
| Avg | 0.1% | 5.3% | |||
| Low | -4.3% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.02 | 0.20 | |||
| Avg | 0.01 | 0.07 | |||
| Low | - | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,163.8% | |||
| Avg | - | 669.2% | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.